All In Biotech

Drug Trial Radar · NCT00570739

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes

Last checked: Nov 19, 2026Latest source record: Jul 27, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

502

Actual

Start

Nov 2007

Primary completion

Apr 2009

Study completion May 2009

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Dec 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects. Diabetic participants will also be treated with open label, background,metformin HCl. Two-hundred sixty subjects with type 2 diabetes (T2DM) and 200 pre-diabetic subjects are planned to be be enrolled. Qualified subjects with T2DM will be randomized 1:1 to receive metformin HCl plus colesevelam HCl or metformin HCl plus placebo matching colesevelam HCl. Qualified pre-diabetic subjects will be randomized 1:1 to receive colesevelam HCl or matching placebo.

Conditions

  • Type 2 Diabetes Mellitus
  • Hypercholesterolemia
  • Pre-diabetes

Interventions

  • Metformin HCl and Colesevelam PlaceboDrug

    One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks

  • Metformin HCl tablets and Colesevelam tabletsDrug

    One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks

  • Colesevelam placeboDrug

    Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks

  • ColesevelamDrug

    Six colesevelam 625 mg tablets will be given once a day for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-naïve, Diabetic Subjects.Time frame: Baseline to 16 weeks
  2. Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 WeeksTime frame: Baseline to 16 Weeks

Locations

31 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Los Gatos, California

  • Site not named

    Tarzana, California

  • Site not named

    Ocala, Florida

  • Site not named

    Pocatello, Idaho

  • Site not named

    Gary, Indiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Olive Branch, Mississippi

  • Site not named

    Dundee, New York

  • Site not named

    West Seneca, New York

  • Site not named

    Statesville, North Carolina

  • Site not named

    Kent, Ohio

  • Site not named

    Marion, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Corpus Christi, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Barranquilla, Atlántico, Colombia

  • Site not named

    Bogota, Cundinamarca, Colombia

  • Site not named

    Bucaramanga, Santander Department, Colombia

  • Site not named

    Mumbai, Dadar, India

  • Site not named

    Durgāpura, Jaipur, India

  • Site not named

    Bangalore, Karnataka, India

  • Site not named

    Kochi, Kerala, India

  • Site not named

    Nashik, Maharashtra, India

  • Site not named

    Las Palmas, Chihuahua, Mexico

  • Site not named

    Delegacion, Cuauhtemoc, Mexico

  • Site not named

    Guadalajara, Jalisco, Mexico

  • Site not named

    Monterrey, Nuevo León, Mexico

  • Site not named

    Hermosillo, Sonora, Mexico

  • Site not named

    Mérida, Yucatán, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.